Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 363

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1B
Chunk 363
---
 creates an environment that is more conducive
to objective evaluation and oversight of management’s performance, increasing management accountability and improving the ability
of the Board to monitor whether management’s actions are in the best interests of the Company and its stockholders. Furthermore,
we believe that Dr. Pomerantz is especially suited to serve as our Chairman of the Board, in light of his significant strategic management
experience in the U.S. healthcare industry, which provides him with a unique perspective on the best methods of growth for a life sciences
company.

However,
our Board of Directors will continue to periodically review our leadership structure and may make such changes in the future as it deems
appropriate.

Role
of the Board in Risk Oversight

One
of the key functions of our Board is informed oversight of our risk management process. Our Board does not have a standing risk management
committee, but rather administers this oversight function directly through our Board as a whole, as well as through various standing
committees of our Board that address risks inherent in their respective areas of oversight. In particular, our Board is responsible for
monitoring and assessing strategic risk exposure. Our Board considers cybersecurity risk as part of its risk oversight function and oversees
our cybersecurity and other information technology risks and management’s implementation of our cybersecurity risk management program.
Our Audit Committee has the responsibility to consider and discuss our major financial risk exposures and the steps management will take
to monitor and control such exposures, including guidelines and policies to govern the process by which risk assessment and management
is undertaken. The Audit Committee also monitors compliance with legal and regulatory requirements and considers and approves or disapproves
any related person transactions. Our Compensation Committee assesses and monitors whether our compensation plans, policies and programs
comply with applicable legal and regulatory requirements. The Board does not believe that its role in the oversight of our risks affects
the Board’s leadership structure.

76

Clawback
Policy

Our
Board of Directors has adopted a Policy for Recovery of Erroneously Awarded Compensation (the “Clawback Policy”), in accordance
with the Nasdaq listing standards and Exchange Act Rule 10D-1, which applies to our current and former executive officers. Under the
Clawback Policy, we are required to recoup the amount of any Erroneously Awarded Compensation (as defined in the Clawback Policy) on
a pre-tax basis within a specified lookback period in the event of any Financial Restatement (as defined in the Clawback Policy), subject
to limited impr